Related Experiment Video

Updated: Jul 18, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Unlocking the Potential of Kinase Targets in Cancer: Insights from CancerOmicsNet, an AI-Driven Approach to Drug

Manali Singha1, Limeng Pu2, Gopal Srivastava1

  • 1Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA.

Cancers
|August 26, 2023
PubMed

Insights

Researchers developed CancerOmicsNet, an AI model predicting cancer cell response to kinase inhibitors. This tool, using explainable AI, identifies crucial kinases for targeted cancer therapies, aiding drug discovery for various cancer types.

Area of Science:

  • Oncology
  • Bioinformatics
  • Artificial Intelligence

Background:

  • Deregulated protein kinases drive cancer cell proliferation and signaling.
  • Targeting kinases is crucial for cancer therapy, but only a fraction of the human kinome is drugged.
  • A scoring system is needed to prioritize clinically relevant kinases.

Purpose of the Study:

  • To develop and validate CancerOmicsNet, an AI model for predicting cancer cell response to kinase inhibitors.
  • To utilize explainable AI (saliency maps) to understand kinase contributions within the model.
  • To identify essential kinases as potential therapeutic targets for diverse cancer types.

Main Methods:

  • Developed CancerOmicsNet, an AI model using graph-based algorithms to predict drug response.
  • Evaluated model performance through large-scale benchmarking and experimental validation.
  • Employed customized saliency maps for explainable AI analysis of kinase importance.

Main Results:

  • CancerOmicsNet accurately predicts cancer cell response to kinase inhibitors.
  • Saliency maps successfully identified essential kinases involved in tumor progression.
  • Model predictions were experimentally validated across multiple cancer types.

Conclusions:

  • CancerOmicsNet is a valuable tool for prioritizing kinase targets in cancer therapy.
  • Explainable AI enhances understanding of kinase roles in cancer.
  • The model facilitates the identification of novel druggable targets for cancer treatment.
Keywords:
CancerOmicsNetcancerdruggable targetsexplainable artificial intelligencekinase inhibitorsprotein kinasessaliency map

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K